Colin L Masters

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8651950/publications.pdf

Version: 2024-02-01

521 papers	54,984 citations	1704 104 h-index	1568 217 g-index
567 all docs	567 docs citations	567 times ranked	37287 citing authors

#	Article	IF	Citations
1	The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature, 1987, 325, 733-736.	27.8	4,546
2	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	27.0	3,005
3	Amyloid Î² deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2013, 12, 357-367.	10.2	1,738
4	Soluble pool of A? amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Annals of Neurology, 1999, 46, 860-866.	5.3	1,721
5	Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Î²-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice. Neuron, 2001, 30, 665-676.	8.1	1,419
6	Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell, 1989, 57, 115-126.	28.9	1,249
7	Alzheimer's disease. Nature Reviews Disease Primers, 2015, 1, 15056.	30.5	1,210
8	High performance plasma amyloid-Î² biomarkers for Alzheimerâ€™s disease. Nature, 2018, 554, 249-254.	27.8	1,180
9	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 2010, 31, 1275-1283.	3.1	885
10	Â-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 2007, 130, 2837-2844.	7.6	739
11	Longitudinal assessment of AÎ² and cognition in aging and Alzheimer disease. Annals of Neurology, 2011, 69, 181-192.	5.3	730
12	Distinct sites of intracellular production for Alzheimer's disease AÎ²40/42 amyloid peptides. Nature Medicine, 1997, 3, 1016-1020.	30.7	716
13	Safety, efficacy, and biomarker findings of PBT2 in targeting AÎ² as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2008, 7, 779-786.	10.2	657
14	Imaging of amyloid Î² in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurology, The, 2008, 7, 129-135.	10.2	631
15	Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial AÎ². Neuron, 2008, 59, 43-55.	8.1	629
16	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	30.7	610
17	Iron-Export Ferroxidase Activity of Î²-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease. Cell, 2010, 142, 857-867.	28.9	597
18	Alzheimer's Disease Amyloid-Î² Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits. Journal of Biological Chemistry, 2001, 276, 20466-20473.	3.4	595

#	Article	IF	Citations
19	A systemic view of Alzheimer disease â€" insights from amyloid-Î² metabolism beyond the brain. Nature Reviews Neurology, 2017, 13, 612-623.	10.1	581
20	Metalloenzyme-like Activity of Alzheimer's Disease Î²-Amyloid. Journal of Biological Chemistry, 2002, 277, 40302-40308.	3.4	536
21	The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	7.9	478
22	Analysis of Heterogeneous Î²A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay. Journal of Biological Chemistry, 1996, 271, 22908-22914.	3.4	461
23	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652.	10.1	434
24	Tau imaging: early progress and future directions. Lancet Neurology, The, 2015, 14, 114-124.	10.2	432
25	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.1	391
26	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
27	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	5.3	381
28	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
29	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Archives of Neurology, 2012, 69, 1318.	4.5	348
30	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. Journal of Alzheimer's Disease, 2010, 20, 509-516.	2.6	347
31	Cytosolic Î²-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet, The, 2003, 361, 1258-1265.	13.7	323
32	Relationship between atrophy and Î²â€amyloid deposition in Alzheimer disease. Annals of Neurology, 2010, 67, 317-324.	5.3	322
33	Imaging tau and amyloid-Î² proteinopathies in Alzheimer disease and other conditions. Nature Reviews Neurology, 2018, 14, 225-236.	10.1	321
34	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimerâ€™s Disease. Science Translational Medicine, 2014, 6, 226ra30.	12.4	320
35	Amyloid Imaging with ¹⁸F-Florbetaben in Alzheimer Disease and Other Dementias. Journal of Nuclear Medicine, 2011, 52, 1210-1217.	5.0	311
36	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	7.1	309

#	Article	IF	Citations
37	Degradation of the Alzheimer Disease Amyloid Î²-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity. Journal of Biological Chemistry, 2006, 281, 17670-17680.	3.4	267
38	Harmonization of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan. NeuroImage, 2020, 208, 116450.	4.2	260
39	Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease Î²â€amyloid. FASEB Journal, 2004, 18, 1427-1429.	0.5	251
40	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience, 2019, 22, 1903-1912.	14.8	242
41	Dopamine promotes Î±â€synuclein aggregation into SDSâ€resistant soluble oligomers via a distinct folding pathway. FASEB Journal, 2005, 19, 1377-1379.	0.5	239
42	Non-invasive assessment of Alzheimerâ€™s disease neurofibrillary pathology using 18F-THK5105 PET. Brain, 2014, 137, 1762-1771.	7.6	234
43	The role of metallobiology and amyloidâ€Î² peptides in Alzheimerâ€™s disease. Journal of Neurochemistry, 2012, 120, 149-166.	3.9	233
44	The Î²A4 amyloid precursor protein binding to copper. FEBS Letters, 1994, 349, 109-116.	2.8	230
45	Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nature Structural Biology, 1999, 6, 327-331.	9.7	229
46	Pleomorphic Copper Coordination by Alzheimerâ€™s Disease Amyloid-Î² Peptide. Journal of the American Chemical Society, 2009, 131, 1195-1207.	13.7	228
47	Increased Cerebral Glucose-6-Phosphate Dehydrogenase Activity in Alzheimer's Disease May Reflect Oxidative Stress. Journal of Neurochemistry, 1986, 46, 1042-1045.	3.9	224
48	Regional dynamics of amyloid-Î² deposition in healthy elderly, mild cognitive impairment and Alzheimerâ€™s disease: a voxelwise PiBâ€“PET longitudinal study. Brain, 2012, 135, 2126-2139.	7.6	222
49	Mechanisms of AÎ² mediated neurodegeneration in Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2008, 40, 181-198.	2.8	220
50	A rigorous method to enrich for exosomes from brain tissue. Journal of Extracellular Vesicles, 2017, 6, 1348885.	12.2	218
51	Cerebral quantitative susceptibility mapping predicts amyloid-Î²-related cognitive decline. Brain, 2017, 140, 2112-2119.	7.6	213
52	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. Journal of Neurochemistry, 2006, 97, 1700-1725.	3.9	206
53	Interaction of the Molecular Chaperone Î±B-Crystallin with Î±-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity. Journal of Molecular Biology, 2004, 340, 1167-1183.	4.2	198
54	The solubility of Î±-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. Journal of Neurochemistry, 2008, 76, 87-96.	3.9	196

#	Article	IF	Citations
55	Predicting Alzheimer disease with Î²â€amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology, 2013, 74, 905-913.	5.3	194
56	Utility of an improved model of amyloid-beta (AÎ²1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimerâ€™s disease. Molecular Neurodegeneration, 2012, 7, 57.	10.8	188
57	MRI signatures of brain age and disease over the lifespan based on a deep brain network and 14â€‰468 individuals worldwide. Brain, 2020, 143, 2312-2324.	7.6	183
58	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimerâ€™s disease. Brain, 2014, 137, 221-231.	7.6	182
59	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
60	Amyloid Precursor Protein (APP) and Î'ZA4 Amyloid in the Etiology of Alzheimer's Disease: Precursorâ€Product Relationships in the Derangement of Neuronal Function. Brain Pathology, 1991, 1, 241-251.	4.1	181
61	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
62	Concentration Dependent Cu2+Induced Aggregation and Dityrosine Formation of the Alzheimer's Disease Amyloid-Î² Peptideâ€. Biochemistry, 2007, 46, 2881-2891.	2.5	179
63	Neurotoxic, Redox-competent Alzheimer's Î²-Amyloid Is Released from Lipid Membrane by Methionine Oxidation. Journal of Biological Chemistry, 2003, 278, 42959-42965.	3.4	176
64	Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations. Frontiers in Neurology, 2014, 4, 205.	2.4	176
65	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurology, The, 2016, 15, 1044-1053.	10.2	175
66	Non-AÎ² Component of Alzheimer's Disease Amyloid (NAC) Revisited. American Journal of Pathology, 1999, 155, 1173-1181.	3.8	173
67	Copper-mediated Amyloid-Î² Toxicity Is Associated with an Intermolecular Histidine Bridge. Journal of Biological Chemistry, 2006, 281, 15145-15154.	3.4	170
68	Cross-sectional and Longitudinal Analysis of the Relationship Between AÎ² Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. JAMA Neurology, 2013, 70, 903.	9.0	170
69	Sex, amyloid, and APOE Îµ4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three wellâ€characterized cohorts. Alzheimer's and Dementia, 2018, 14, 1193-1203.	0.8	169
70	The Alzheimerâ€™s therapeutic PBT2 promotes amyloidâ€Î² degradation and GSK3 phosphorylation via a metal chaperone activity. Journal of Neurochemistry, 2011, 119, 220-230.	3.9	167
71	Alanine-2 Carbonyl is an Oxygen Ligand in Cu²⁺ Coordination of Alzheimerâ€™s Disease Amyloid-Î² Peptide â^' Relevance to N-Terminally Truncated Forms. Journal of the American Chemical Society, 2009, 131, 8760-8761.	13.7	163
72	Comparison of 11C-PiB and 18F-florbetaben for AÎ² imaging in ageing and Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 983-989.	6.4	161

#	Article	IF	Citations
73	Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2014, 34, 8021-8031.	3.6	161
74	Amyloid-Î², Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. JAMA Psychiatry, 2015, 72, 284.	11.0	160
75	Copper inhibits Î²-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochemical Journal, 1999, 344, 461-467.	3.7	158
76	Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimerâ€™s disease. Nature Communications, 2019, 10, 4227.	12.8	157
77	High Striatal Amyloid Î²-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types. Archives of Neurology, 2009, 66, 1537-44.	4.5	156
78	In vivo evaluation of a novel tau imaging tracer for Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 816-826.	6.4	156
79	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
80	In VitroCharacterization of Pittsburgh Compound-B Binding to Lewy Bodies. Journal of Neuroscience, 2007, 27, 10365-10371.	3.6	154
81	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimerâ€™s disease. BMC Psychology, 2013, 1, 30.	2.1	153
82	The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinsonâ€™s disease. Journal of Experimental Medicine, 2012, 209, 837-854.	8.5	151
83	Amyloidogenicity of rodent and human Î²A4 sequences. FEBS Letters, 1993, 324, 231-236.	2.8	148
84	Syndromes of amyotrophic lateral sclerosis and dementia: Relation to transmissible Creutzfeldt-Jakob disease. Annals of Neurology, 1983, 14, 17-26.	5.3	147
85	Head-to-Head Comparison of ¹¹C-PiB and ¹⁸F-AZD4694 (NAV4694) for Î²-Amyloid Imaging in Aging and Dementia. Journal of Nuclear Medicine, 2013, 54, 880-886.	5.0	145
86	Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. Journal of Neuroscience Research, 2003, 74, 386-392.	2.9	142
87	Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the AÂ amyloid pathway. Brain, 2006, 129, 2823-2839.	7.6	141
88	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia, 2011, 49, 2384-2390.	1.6	139
89	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 796-804.	0.8	135
90	Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimerâ€™s disease. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 1213-1221.	1.9	133

#	Article	IF	Citations
91	Independent contribution of temporal Î²-amyloid deposition to memory decline in the pre-dementia phase of Alzheimerâ€™s disease. Brain, 2011, 134, 798-807.	7.6	132
92	Cognitive impairment and decline in cognitively normal older adults with high amyloidâ€Î²: A metaâ€analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 108-121.	2.4	131
93	Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain, 2010, 133, 3349-3358.	7.6	130
94	Plasma amyloid Î² 42/40 ratios as biomarkers for amyloid Î² cerebral deposition in cognitively normal individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 179-187.	2.4	129
95	Copper-Binding Amyloid Precursor Protein Undergoes a Site-Specific Fragmentation in the Reduction of Hydrogen Peroxideâ€. Biochemistry, 1998, 37, 7224-7230.	2.5	128
96	Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology, 2014, 82, 1266-1273.	1.1	125
97	The Relationship between Sleep Quality and Brain Amyloid Burden. Sleep, 2016, 39, 1063-1068.	1.1	123
98	Biochemically-defined pools of amyloid-Î² in sporadic Alzheimerâ€™s disease: correlation with amyloid PET. Brain, 2017, 140, 1486-1498.	7.6	123
99	Plasma Amyloid-Î² as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. Journal of Alzheimer's Disease, 2010, 20, 1233-1242.	2.6	122
100	The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from Î³-secretase. FEBS Journal, 2001, 268, 5329-5336.	0.2	116
101	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	7.6	116
102	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 53-61.	0.8	114
103	The Amyloid Î²â€Protein of Alzheimer's Disease Increases Acetylcholinesterase Expression by Increasing Intracellular Calcium in Embryonal Carcinoma P19 Cells. Journal of Neurochemistry, 1997, 69, 1177-1184.	3.9	112
104	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	9.0	112
105	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 345-358.	1.3	111
106	BDNF Val66Met, AÎ² amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	3.1	109
107	The Caenorhabditis elegans AÎ²1â€“42 Model of Alzheimer Disease Predominantly Expresses AÎ²3â€“42. Journal of Biological Chemistry, 2009, 284, 22697-22702.	3.4	108
108	Formation of dopamine-mediated Î±-synuclein-soluble oligomers requires methionine oxidation. Free Radical Biology and Medicine, 2009, 46, 1328-1337.	2.9	104

#	Article	IF	Citations
109	Mutations in the Transmembrane Domain of APP Altering Î³-Secretase Specificityâ€. Biochemistry, 1997, 36, 15396-15403.	2.5	102
110	Total AÎ² ₄₂ /AÎ² ₄₀ ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology, 2020, 94, e1580-e1591.	1.1	102
111	Retinoic acid induced differentiated neuroblastoma cells show increased expression of the Î²A4 amyloid gene of Alzheimer's disease and an altered splicing pattern. FEBS Letters, 1990, 269, 305-310.	2.8	101
112	Cu²⁺Binding Modes of Recombinant Î±-Synuclein â^' Insights from EPR Spectroscopy. Journal of the American Chemical Society, 2008, 130, 7766-7773.	13.7	100
113	Crystal Structure of the Amyloid-Î² p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 1419-1426.	3.6	99
114	An ironâ€“dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chemical Science, 2014, 5, 2160-2169.	7.4	98
115	Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology, 2012, 79, 1645-1652.	1.1	96
116	Comparison of MR-less PiB SUVR quantification methods. Neurobiology of Aging, 2015, 36, S159-S166.	3.1	96
117	AÎ²-amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	4.6	96
118	Alzheimerâ€™s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategiesâ€”Gains from AIBL and DIAN Cohort Studies. Journal of Alzheimer's Disease, 2018, 62, 965-992.	2.6	96
119	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.1	96
120	The ART of Loss: AÎ² Imaging in the Evaluation of Alzheimerâ€™s Disease and other Dementias. Molecular Neurobiology, 2008, 38, 1-15.	4.0	94
121	Implementing the centiloid transformation for 11C-PiB and Î²-amyloid 18F-PET tracers using CapAIBL. NeuroImage, 2018, 183, 387-393.	4.2	94
122	Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: Implications for Alzheimer Î²-amyloid pathology. Journal of Inorganic Biochemistry, 2006, 100, 952-962.	3.5	93
123	Ammonium hydroxide treatment of AÎ² produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ, 2013, 1, e73.	2.0	93
124	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain AÎ²-amyloid burden. Translational Psychiatry, 2018, 8, 47.	4.8	92
125	Variable phenotype of Alzheimer's disease with spastic paraparesis. Annals of Neurology, 2001, 49, 125-129.	5.3	90
126	Copper Promotes the Trafficking of the Amyloid Precursor Protein. Journal of Biological Chemistry, 2011, 286, 8252-8262.	3.4	90

#	Article	IF	Citations
127	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). Archives of Clinical Neuropsychology, 2013, 28, 320-330.	0.5	90
128	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1141-1154.	0.8	89
129	Validation of Plasma Amyloid-Î² 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology, 2022, 98, .	1.1	89
130	The structure of dopamine induced Î±-synuclein oligomers. European Biophysics Journal, 2010, 39, 1407-1419.	2.2	87
131	An increased neutrophilâ€“lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. Journal of Neuroimmunology, 2014, 273, 65-71.	2.3	87
132	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	10.2	87
133	18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2053-2059.	6.4	87
134	Interaction between the zinc(II) and the heparin binding site of the Alzheimer's disease Î²A4 amyloid precursor protein (APP). FEBS Letters, 1994, 355, 151-154.	2.8	86
135	Restored degradation of the Alzheimerâ€™s amyloidâ€Î² peptide by targeting amyloid formation. Journal of Neurochemistry, 2009, 108, 1198-1207.	3.9	85
136	Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimerâ€™s Disease: What are the Roadblocks and How Can They Be Overcome?1. Journal of Alzheimer's Disease, 2015, 47, 815-843.	2.6	84
137	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	2.4	84
138	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. Journal of Alzheimer's Disease, 2011, 27, 909-922.	2.6	83
139	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	7.6	83
140	The Nosology of Creutzfeldtâ€Jakob Disease and Conditions Related to the Accumulation of PrP^{CJD} in the Nervous System. Brain Pathology, 1995, 5, 33-41.	4.1	82
141	Novel Leu723Pro amyloid precursor protein mutation increases amyloid ?42(43) peptide levels and induces apoptosis. Annals of Neurology, 2000, 47, 249-253.	5.3	82
142	The Neurobiology and Age-Related Prevalence of the Îµ4 Allele of Apolipoprotein E in Alzheimerâ€™s Disease Cohorts. Journal of Molecular Neuroscience, 2016, 60, 316-324.	2.3	82
143	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage, 2008, 43, 430-439.	4.2	81
144	Exacerbation of Copper Toxicity in Primary Neuronal Cultures Depleted of Cellular Glutathione. Journal of Neurochemistry, 2008, 72, 2092-2098.	3.9	79

#	Article	IF	Citations
145	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	7.6	79
146	AÎ² imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 431-436.	1.9	78
147	The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2017, 5, 53.	5.2	77
148	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. Journal of Alzheimer's Disease, 2014, 39, 661-668.	2.6	76
149	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 5698.	12.8	76
150	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimerâ€™s Disease: A Preliminary Study. PLoS ONE, 2014, 9, e86498.	2.5	75
151	Decreased Plasma Iron in Alzheimerâ€™s Disease Is Due to Transferrin Desaturation. ACS Chemical Neuroscience, 2015, 6, 398-402.	3.5	75
152	APOE Îµ4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1239-1244.	3.1	75
153	Intracellular Accumulation of Detergent-Soluble Amyloidogenic AÎ² Fragment of Alzheimer's Disease Precursor Protein in the Hippocampus of Aged Transgenic Mice. Journal of Neurochemistry, 2002, 72, 2479-2487.	3.9	74
154	Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn2+ complexes in Alzheimer's disease. Aging Cell, 2006, 5, 69-79.	6.7	74
155	Amyloid-Î² Peptide AÎ²3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. Journal of Biological Chemistry, 2016, 291, 6134-6145.	3.4	74
156	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 22.	6.2	74
157	The amyloid precursor protein of Alzheimer disease in human brain and blood. Journal of Leukocyte Biology, 1999, 66, 567-574.	3.3	73
158	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology, 2019, 92, e1567-e1579.	1.1	73
159	Human and rodent sequence analogs of Alzheimer's amyloid betaA4 share similar properties and can be solubilized in buffers of pH 7.4. FEBS Journal, 1991, 201, 61-69.	0.2	72
160	Evaluating Atypical Dementia Syndromes Using Positron Emission Tomography With Carbon 11â€“Labeled Pittsburgh Compound B. Archives of Neurology, 2007, 64, 1140.	4.5	72
161	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Zâ€scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 19-26.	2.4	72
162	Synthesis and secretion of Alzheimer amyloid Î²A4 precursor protein by stimulated human peripheral blood leucocytes. FEBS Letters, 1990, 277, 261-266.	2.8	71

#	Article	IF	Citations
163	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiology of Aging, 2015, 36, 1231-1238.	3.1	71
164	Blood-Borne Amyloid-Î² Dimer Correlates with Clinical Markers of Alzheimer's Disease. Journal of Neuroscience, 2010, 30, 6315-6322.	3.6	70
165	Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies. Current Neurology and Neuroscience Reports, 2014, 14, 499.	4.2	70
166	BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	7.6	70
167	Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry. Analytical Chemistry, 2017, 89, 6136-6145.	6.5	70
168	Association of Î²-Amyloid and Apolipoprotein E Îµ4 With Memory Decline in Preclinical Alzheimer Disease. JAMA Neurology, 2018, 75, 488.	9.0	70
169	Alzheimer's disease-associated presenilin 1 in neuronal cells: Evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment. , 1997, 49, 719-731.		68
170	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.1	67
171	Early behavioural changes in familial Alzheimerâ€™s disease in the Dominantly Inherited Alzheimer Network. Brain, 2015, 138, 1036-1045.	7.6	67
172	Stabilization of Nontoxic AÂ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease. Journal of Neuroscience, 2015, 35, 2871-2884.	3.6	67
173	Identification of Heparinâ€Binding Domains in the Amyloid Precursor Protein of Alzheimer's Disease by Deletion Mutagenesis and Peptide Mapping. Journal of Neurochemistry, 1997, 68, 1164-1172.	3.9	66
174	AÎ² and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 743.	0.8	66
175	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	6.9	64
176	Characterization of brainâ€derived extracellular vesicle lipids in Alzheimer's disease. Journal of Extracellular Vesicles, 2021, 10, e12089.	12.2	64
177	Amyloid-Î² Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. Journal of Alzheimer's Disease, 2014, 43, 677-686.	2.6	63
178	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid-Î². Journal of Alzheimer's Disease, 2013, 33, 675-679.	2.6	62
179	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
180	Mouse-adapted sporadic human Creutzfeldtâ€“Jakob disease prions propagate in cell culture. International Journal of Biochemistry and Cell Biology, 2008, 40, 2793-2801.	2.8	59

#	Article	IF	Citations
181	Factors Associated With the Onset and Persistence of Postâ€“Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	9.0	59
182	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Scientific Reports, 2017, 7, 9766.	3.3	59
183	A randomized, exploratory molecular imaging study targeting amyloid Î² with a novel 8â€OH quinoline in Alzheimer's disease: The PBT2â€204 IMAGINE study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 622-635.	3.7	59
184	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimerâ€™s disease. Science Advances, 2019, 5, eaau7220.	10.3	59
185	Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles. Journal of Extracellular Vesicles, 2020, 9, 1766822.	12.2	59
186	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 443-468.	2.2	59
187	Irregular distribution of cytochromec oxidase protein subunits in aging and Alzheimer's disease. Annals of Neurology, 1999, 46, 656-660.	5.3	58
188	Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurology, 2014, 83, 1345-1352.	1.1	58
189	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. Brain, 2016, 139, 2528-2539.	7.6	58
190	Characterization of the high affinity heparin binding site of the Alzheimer's disease Î²A4 amyloid precursor protein (APP) and its enhancement by zinc(II). Journal of Molecular Recognition, 1995, 8, 247-257.	2.1	57
191	Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer's disease frontal cortex. NeuroImage, 2016, 137, 124-131.	4.2	57
192	An abnormality of plasma amyloid protein precursor in Alzheimer's disease. Annals of Neurology, 1992, 32, 57-65.	5.3	56
193	Development of a Platinum Complex as an antiâ€Amyloid Agent for the Therapy of Alzheimerâ€™s Disease. Angewandte Chemie - International Edition, 2013, 52, 3374-3378.	13.8	56
194	Human Amyloid Precursorâ€Like Protein 1. FEBS Journal, 1997, 250, 354-363.	0.2	55
195	Paradoxical Condensation of Copper with Elevated Î²-Amyloid in Lipid Rafts under Cellular Copper Deficiency Conditions. Journal of Biological Chemistry, 2009, 284, 21899-21907.	3.4	55
196	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimer's and Dementia, 2020, 16, 552-560.	0.8	55
197	In-vitro matured human macrophages express Alzheimer's Î²A4-amyloid precursor protein indicating synthesis in microglial cells. FEBS Letters, 1991, 282, 335-340.	2.8	54
198	Proteolytic Fragments of Alzheimerâ€™s Diseaseâ€Associated Presenilin 1 Are Present in Synaptic Organelles and Growth Cone Membranes of Rat Brain. Journal of Neurochemistry, 1999, 72, 1564-1573.	3.9	54

#	Article	IF	Citations
199	In vitro characterization of [18F]-florbetaben, an AÎ² imaging radiotracer. Nuclear Medicine and Biology, 2012, 39, 1042-1048.	0.6	54
200	Mixed Ligand Cu2+Complexes of a Model Therapeutic with Alzheimerâ€™s Amyloid-Î² Peptide and Monoamine Neurotransmitters. Inorganic Chemistry, 2013, 52, 4303-4318.	4.0	54
201	Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). Journal of Alzheimer's Disease, 2017, 57, 183-193.	2.6	54
202	Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrPC. Journal of Neuroscience Research, 2000, 62, 293-301.	2.9	53
203	Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2010, 6, 291-296.	0.8	53
204	AÎ² amyloid, cognition, and APOE genotype in healthy older adults. Alzheimer's and Dementia, 2013, 9, 538-545.	0.8	51
205	Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging. Archives of Clinical Neuropsychology, 2017, 32, 142-154.	0.5	51
206	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.8	51
207	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	2.5	51
208	Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of Î²-Amyloid Toxicity and Are Mediated by Tau. Neurotherapeutics, 2015, 12, 862-873.	4.4	50
209	Comparison of ¹⁸Fâ€florbetaben quantification results using the standard Centiloid, MRâ€based, and MRâ€less CapAIBL^{Â®} approaches: Validation against histopathology. Alzheimer's and Dementia, 2019, 15, 807-816.	0.8	50
210	Human Brain ?A4 Amyloid Protein Precursor of Alzheimer's Disease: Purification and Partial Characterization. Journal of Neurochemistry, 1992, 59, 1490-1498.	3.9	49
211	Investigation of Matrix Metalloproteinases, MMP-2 and MMP-9, in Plasma Reveals a Decrease of MMP-2 in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 779-786.	2.6	49
212	18F-florbetaben AÎ² imaging in mild cognitive impairment. Alzheimer's Research and Therapy, 2013, 5, 4.	6.2	49
213	Amyloid burden and incident depressive symptoms in cognitively normal older adults. International Journal of Geriatric Psychiatry, 2017, 32, 455-463.	2.7	49
214	Mediterranean diet adherence and rate of cerebral AÎ²-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Translational Psychiatry, 2018, 8, 238.	4.8	49
215	Rapid cellular uptake of Alzheimer amyloid Î²A4 peptide by cultured human neuroblastoma cells. FEBS Letters, 1996, 394, 174-178.	2.8	48
216	Expression and analysis of heparin-binding regions of the amyloid precursor protein of Alzheimer's disease. FEBS Letters, 1997, 415, 303-307.	2.8	48

#	Article	IF	Citations
217	The APOE Îµ4 Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2017, 8, 1459-1464.	3.5	48
218	SubstrateâBound Î²â€Amyloid Peptides Inhibit Cell Adhesion and Neurite Outgrowth in Primary Neuronal Cultures. Journal of Neurochemistry, 2000, 74, 1122-1130.	3.9	47
219	Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. Journal of Neuroscience Research, 2001, 65, 565-572.	2.9	47
220	Alzheimerâ€™s Disease Normative Cerebrospinal Fluid Biomarkers Validated inÂPET Amyloid-Î² Characterized Subjects from the Australian Imaging, Biomarkers andÂLifestyle (AIBL) study. Journal of Alzheimer's Disease, 2015, 48, 175-187.	2.6	47
221	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâinformed machineâlearning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.8	47
222	Transforming growth factor Î² mediates increase of mature transmembrane amyloid precursor protein in microglial cells. FEBS Letters, 1994, 342, 267-272.	2.8	46
223	The ins and outs of amyloid-Î². Nature, 1997, 389, 677-678.	27.8	46
224	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 171-182.	2.6	46
225	The effect of paraformaldehyde fixation and sucrose cryoprotection on metal concentration in murine neurological tissue. Journal of Analytical Atomic Spectrometry, 2014, 29, 565-570.	3.0	45
226	Subjective Memory Complaints in APOE É›4 Carriers are Associated with High Amyloid-Î² Burden. Journal of Alzheimer's Disease, 2016, 49, 1115-1122.	2.6	45
227	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
228	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1197-1206.	0.8	45
229	Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-Î². Journal of Alzheimer's Disease, 2018, 61, 1589-1598.	2.6	44
230	Gelatinase A possesses a Î²-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. FEBS Letters, 1995, 377, 267-270.	2.8	43
231	Relationship between Memory Performance and Î²-Amyloid Deposition at Different Stages of Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2012, 10, 141-144.	1.4	43
232	MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET. PLoS ONE, 2014, 9, e84777.	2.5	43
233	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimerâ€™s disease.. Neuropsychology, 2015, 29, 571-581.	1.3	43
234	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-Î². Journal of Alzheimer's Disease, 2013, 34, 861-871.	2.6	42

#	Article	IF	Citations
235	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	3.3	42
236	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.8	42
237	Alzheimer's Disease and the Early Signs of Age-Related Macular Degeneration. Current Alzheimer Research, 2016, 13, 1259-1266.	1.4	42
238	Plasma Amyloid-Î² Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. Journal of Alzheimer's Disease, 2014, 40, 95-104.	2.6	41
239	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. BMC Psychiatry, 2012, 12, 167.	2.6	40
240	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and AÂ Accumulation in Cognitively Normal Older Adults and Adults with MCI. Archives of Clinical Neuropsychology, 2015, 30, 49-58.	0.5	40
241	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 377-389.	7.7	40
242	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A â€˜C-reactive proteinâ€™ for psychiatrists and neurologists?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 57-67.	2.3	40
243	Alzheimer's AÎ² Peptides with Disease-Associated N-Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu2+ Coordination. PLoS ONE, 2010, 5, e15875.	2.5	40
244	Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics, 2013, 5, 1656.	2.4	39
245	Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 29078.	3.3	39
246	Rubidium and potassium levels are altered in Alzheimerâ€™s disease brain and blood but not in cerebrospinal fluid. Acta Neuropathologica Communications, 2016, 4, 119.	5.2	39
247	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimer's Research and Therapy, 2020, 12, 36.	6.2	39
248	Deep Generative Medical Image Harmonization for Improving Crossâ€Site Generalization in Deep Learning Predictors. Journal of Magnetic Resonance Imaging, 2022, 55, 908-916.	3.4	38
249	A deep learning framework identifies dimensional representations of Alzheimerâ€™s Disease from brain structure. Nature Communications, 2021, 12, 7065.	12.8	38
250	Overexpression of AÎ² is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell, 2006, 5, 153-165.	6.7	37
251	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). International Psychogeriatrics, 2014, 26, 543-554.	1.0	37
252	AÎ²-related memory decline in APOE Îµ4 noncarriers. Neurology, 2016, 86, 1635-1642.	1.1	37

#	Article	IF	Citations
253	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2016, 60, 354-361.	2.3	37
254	Decreased Copper in Alzheimerâ€™s Disease Brain Is Predominantly in the Soluble Extractable Fraction. International Journal of Alzheimer's Disease, 2013, 2013, 1-7.	2.0	36
255	A Multi-Cohort Study of ApoE É›4 and Amyloid-Î² Effects on the Hippocampus in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 1159-1174.	2.6	36
256	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	7.6	36
257	Familial Prion Disease Mutation Alters the Secondary Structure of Recombinant Mouse Prion Protein:Â Implications for the Mechanism of Prion Formationâ€. Biochemistry, 1999, 38, 3280-3284.	2.5	35
258	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. Journal of Alzheimer's Disease, 2017, 58, 1293-1302.	2.6	35
259	Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease. Journal of Magnetic Resonance Imaging, 2020, 51, 505-513.	3.4	35
260	Sequence of Alzheimer disease biomarker changes in cognitively normal adults. Neurology, 2020, 95, e3104-e3116.	1.1	35
261	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12005.	2.4	35
262	The Animal Models of Dementia and Alzheimerâ€™s Disease for Pre-Clinical Testing and Clinical Translation. Current Alzheimer Research, 2012, 9, 1010-1029.	1.4	34
263	Cognitive Decline in Adults with Amnestic Mild Cognitive Impairment and High Amyloid-Î²: Prodromal Alzheimer's Disease?. Journal of Alzheimer's Disease, 2013, 33, 1167-1176.	2.6	34
264	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. Metallomics, 2014, 6, 1216-1219.	2.4	34
265	Association of Î²-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. Neurology, 2021, 96, e662-e670.	1.1	34
266	Cognitive consequences of high AÎ² amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimerâ€™s disease.. Neuropsychology, 2013, 27, 322-332.	1.3	33
267	Plasma Cortisol, Brain Amyloid-Î², and Cognitive Decline in Preclinical Alzheimerâ€™s Disease: A 6-Year Prospective Cohort Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 45-52.	1.5	32
268	Genomics of Alzheimerâ€™s disease implicates the innate and adaptive immune systems. Cellular and Molecular Life Sciences, 2021, 78, 7397-7426.	5.4	32
269	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE Îµ4-positive cognitively normal adults with high AÎ²-amyloid burden. Scientific Reports, 2018, 8, 2034.	3.3	31
270	Association of deficits in short-term learning and AÎ² and hippocampal volume in cognitively normal adults. Neurology, 2020, 95, e2577-e2585.	1.1	31

#	Article	IF	Citations
271	Variability in Blood-Based Amyloid-Î² Assays: The Need for Consensus on Pre-Analytical Processing. Journal of Alzheimer's Disease, 2012, 30, 323-336.	2.6	30
272	Progress towards a consensus on biomarkers for Alzheimerâ€™s disease: a review of peripheral analytes. Biomarkers in Medicine, 2013, 7, 641-662.	1.4	30
273	Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers. Current Alzheimer Research, 2013, 10, 790-796.	1.4	30
274	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 18-26.	2.4	30
275	Method comparison study of the ElecsysÂ® Î²-Amyloid (1â€“42) CSF assay versus comparator assays and LC-MS/MS. Clinical Biochemistry, 2019, 72, 7-14.	1.9	30
276	To What Extent Does Age at Death Account for Sex Differences in Rates of Mortality From Alzheimer Disease?. American Journal of Epidemiology, 2019, 188, 1213-1223.	3.4	30
277	Relationship between amyloid and tau levels and its impact on tau spreading. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2225-2232.	6.4	30
278	Amyloid, aluminium and the aetiology of Alzheimer's disease. Medical Journal of Australia, 1995, 163, 256-259.	1.7	29
279	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. British Journal of Psychiatry, 2014, 204, 400-401.	2.8	29
280	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 60-72.	2.4	29
281	Evaluation of Cholinergic Deficiency in Preclinical Alzheimerâ€™s Disease Using Pupillometry. Journal of Ophthalmology, 2017, 2017, 1-8.	1.3	29
282	Effects of the amyloid protein precursor of Alzheimer's disease and other ligands of the LDL receptor-related protein on neurite outgrowth from sympathetic neurons in culture. FEBS Letters, 1998, 428, 13-16.	2.8	28
283	Lack of reliable evidence for a distinctive Îµ4â^'related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. Brain, 2013, 136, 2201-2216.	7.6	28
284	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimerâ€™s Disease Trials: An AIBL Study. Journal of Alzheimer's Disease, 2015, 46, 1079-1089.	2.6	28
285	A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 147-155.	2.4	28
286	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. Journal of Alzheimer's Disease, 2018, 63, 1299-1305.	2.6	28
287	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. Neurobiology of Aging, 2020, 89, 132-141.	3.1	28
288	Longitudinal cognitive decline in the AIBL cohort: The role of APOE Îµ4 status. Neuropsychologia, 2015, 75, 411-419.	1.6	27

#	Article	IF	Citations
289	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.1	27
290	Amyloid burden and incident depressive symptoms in preclinical Alzheimerâ€™s disease. Journal of Affective Disorders, 2018, 229, 269-274.	4.1	27
291	Utility of an Alzheimerâ€™s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimerâ€™s Disease: A Prospective Longitudinal Study. Journal of Alzheimer's Disease, 2018, 66, 1193-1211.	2.6	27
292	Seizures as an early symptom of autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2019, 76, 18-23.	3.1	27
293	Plasma Amyloid-Î² Biomarker Associated with Cognitive Decline in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 1057-1065.	2.6	27
294	Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 2016, 87, 1093-1101.	1.1	26
295	Association of naturally occurring antibodies to Î²-amyloid with cognitive decline and cerebral amyloidosis in Alzheimerâ€™s disease. Science Advances, 2021, 7, .	10.3	26
296	Bundle-specific associations between white matter microstructure and AÎ² and tau pathology in preclinical Alzheimerâ€™s disease. ELife, 2021, 10, .	6.0	26
297	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626.	10.2	26
298	Pupil Response Biomarkers for Early Detection and Monitoring of Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 931-939.	1.4	26
299	Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 740-752.	3.1	25
300	Small angle X-ray scattering analysis of Cu2+-induced oligomers of the Alzheimer's amyloid Î² peptide. Metallomics, 2015, 7, 536-543.	2.4	25
301	Î²-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. American Journal of Geriatric Psychiatry, 2016, 24, 1191-1195.	1.2	25
302	Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	5.3	25
303	Quantification of N-terminal amyloid-Î² isoforms reveals isomers are the most abundant form of the amyloid-Î² peptide in sporadic Alzheimerâ€™s disease. Brain Communications, 2021, 3, fcab028.	3.3	25
304	Rett syndrome: Abnormal membrane-bound lamellated inclusions in neurons and oligodendroglia. American Journal of Medical Genetics Part A, 1988, 29, 365-368.	2.4	24
305	Amyloid precursor protein of Alzheimer's disease: evidence for a stable, full-length, trans-membrane pool in primary neuronal cultures. European Journal of Neuroscience, 1999, 11, 1779-1788.	2.6	24
306	Automated 11C-PiB Standardized Uptake Value Ratio. Academic Radiology, 2008, 15, 1376-1389.	2.5	24

#	Article	IF	Citations
307	The association of AÎ² amyloid and composite cognitive measures in healthy older adults and MCI. International Psychogeriatrics, 2013, 25, 1667-1677.	1.0	24
308	Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study. Molecular BioSystems, 2015, 11, 190-196.	2.9	24
309	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimer's and Dementia, 2022, 18, 2218-2233.	0.8	24
310	Tangle disentanglement. Nature, 1996, 383, 476-477.	27.8	23
311	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. Alzheimer's and Dementia, 2017, 13, 388-398.	0.8	23
312	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid Î²-Associated Cognitive Decline in Older Adults. Archives of Clinical Neuropsychology, 2019, 34, 585-598.	0.5	23
313	Klotho allele status is not associated with AÎ² and APOE Îµ4â€“related cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2019, 76, 162-165.	3.1	23
314	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 303-315.	2.6	23
315	High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 787-799.	1.4	23
316	Amyloid-Related Memory Decline in Preclinical Alzheimerâ€™s Disease Is Dependent on APOE Îµ4 and Is Detectable over 18-Months. PLoS ONE, 2015, 10, e0139082.	2.5	22
317	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimer's Research and Therapy, 2015, 7, 16.	6.2	22
318	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of Î²-amyloid load in an AD cohort. Scientific Reports, 2017, 7, 14057.	3.3	22
319	Ocular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions. , 2018, 59, 3554.		22
320	Collection and normal levels of the amyloid precursor protein in plasma. Annals of Neurology, 1997, 41, 121-124.	5.3	21
321	Glycosaminoglycan Sulphation Affects the Seeded Misfolding of a Mutant Prion Protein. PLoS ONE, 2010, 5, e12351.	2.5	21
322	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. International Psychogeriatrics, 2017, 29, 1825-1834.	1.0	21
323	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimerâ€™s Disease Pathology Between Three Independent Assay Platforms. Journal of Alzheimer's Disease, 2017, 61, 169-183.	2.6	21
324	Genetic resilience to Alzheimer's disease in APOE Îµ4 homozygotes: A systematic review. Alzheimer's and Dementia, 2019, 15, 1612-1623.	0.8	21

#	Article	IF	Citations
325	Rates of ageâ€•and amyloid Î²â€“associated cortical atrophy in older adults with superior memory performance. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 566-575.	2.4	21
326	Influence of Comorbidity of Cerebrovascular Disease and Amyloid-Î² on Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 897-907.	2.6	21
327	Longitudinal evaluation of the natural history of amyloid-Î² in plasma and brain. Brain Communications, 2020, 2, fcaa041.	3.3	21
328	Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. Journal of Neuroscience Research, 1999, 56, 405-419.	2.9	20
329	Pathways to the discovery of the AÎ² amyloid of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 155-161.	2.6	20
330	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20
331	Trajectories of depressive and anxiety symptoms in older adults: a 6â€year prospective cohort study. International Journal of Geriatric Psychiatry, 2018, 33, 405-413.	2.7	20
332	Morphometric Changes to Corneal Dendritic Cells in Individuals With Mild Cognitive Impairment. Frontiers in Neuroscience, 2020, 14, 556137.	2.8	20
333	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
334	Iatrogenic and zoonotic Creutzfeldtâ€“Jakob disease: the Australian perspective. Medical Journal of Australia, 1996, 164, 598-602.	1.7	19
335	Amyloid Î²â€“associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	2.4	19
336	Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. Alzheimer Disease and Associated Disorders, 2018, 32, 190-196.	1.3	19
337	Relationship Between Amyloid-Î² Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	2.6	19
338	Using subjective cognitive decline to identify high global amyloid in communityâ€based samples: A crossâ€cohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 670-678.	2.4	19
339	Plasma transferrin and hemopexin are associated with altered AÎ² uptake and cognitive decline in Alzheimerâ€™s disease pathology. Alzheimer's Research and Therapy, 2020, 12, 72.	6.2	19
340	A six-metabolite panel as potential blood-based biomarkers for Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 94.	5.3	19
341	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. GeroScience, 2022, 44, 1807-1823.	4.6	19
342	Interaction of linear homologous DNA duplexes via Holliday junction formation. FEBS Journal, 2001, 268, 7-14.	0.2	18

#	Article	IF	Citations
343	Sensitivity of a Preclinical Alzheimerâ€™s Cognitive Composite (PACC) to amyloid Î² load in preclinical Alzheimerâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 591-600.	1.3	18
344	A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimerâ€™s Disease: The AIBL Active-Study. Journal of Alzheimer's Disease, 2019, 70, S187-S205.	2.6	18
345	Cerebrospinal fluid neurofilament light chain is elevated in Niemannâ€“Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response. Australian and New Zealand Journal of Psychiatry, 2020, 54, 648-649.	2.3	18
346	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	1.7	18
347	Expression of L-APP mRNA in Brain Cellsa. Annals of the New York Academy of Sciences, 1993, 695, 183-189.	3.8	17
348	Catching the culprit prion. Nature, 1994, 370, 419-420.	27.8	17
349	Alzheimerâ€™s disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). Brain Research, 2002, 940, 49-54.	2.2	17
350	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. Journal of Neuroscience Methods, 2012, 205, 96-109.	2.5	17
351	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. Information Fusion, 2020, 58, 153-167.	19.1	17
352	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
353	Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults.. Neuropsychology, 2019, 33, 964-974.	1.3	17
354	Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral AÎ²-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study. Frontiers in Aging Neuroscience, 2021, 13, 744872.	3.4	17
355	Increasing the Predictive Accuracy of Amyloid-Î² Blood-Borne Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 47-59.	2.6	16
356	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 423.	3.4	16
357	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
358	APOE Îµ2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimer's and Dementia, 2022, 18, 2151-2166.	0.8	16
359	Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. Scientific Reports, 2021, 11, 23788.	3.3	16
360	The Role of Extracellular Matrix in the Processing of the Amyloid Protein Precursor of Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1993, 695, 169-174.	3.8	15

#	Article	IF	Citations
361	The amyloid Î²â€protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domainâ€sensitive trypsinâ€like serine protease in cultures of chick sympathetic neurons. FEBS Journal, 1999, 266, 509-516.	0.2	15
362	Peripheral Î±-Defensins 1 and 2 are Elevated in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1131-1143.	2.6	15
363	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 65, 977-988.	2.6	15
364	Validation of a priori candidate Alzheimerâ€™s disease SNPs with brain amyloid-beta deposition. Scientific Reports, 2019, 9, 17069.	3.3	15
365	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. NeuroImage, 2021, 226, 117593.	4.2	15
366	Comparing amyloid-Î² plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
367	Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	9.0	15
368	Alzheimerâ€™s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. Alzheimer's Research and Therapy, 2015, 7, 71.	6.2	14
369	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. Journal of Molecular Neuroscience, 2016, 60, 362-370.	2.3	14
370	Plasma Amyloid-Î² Peptides in Type 2 Diabetes: A Matched Case-Control Study. Journal of Alzheimer's Disease, 2017, 56, 1127-1133.	2.6	14
371	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. Neurobiology of Aging, 2018, 70, 170-179.	3.1	14
372	BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease. Genes, Brain and Behavior, 2021, 20, e12724.	2.2	14
373	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12307.	2.4	14
374	Subcellular localization of the Alzheimer's disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 79-89.	3.0	13
375	Methionine oxidation: Implications for the mechanism of toxicity of the Î²-amyloid peptide from Alzheimer's disease. International Journal of Peptide Research and Therapeutics, 2003, 10, 413-417.	0.1	13
376	Bayesian Graphical Network Analyses Reveal Complex Biological Interactions Specific to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 917-925.	2.6	13
377	Impact of Mild Head Injury on Neuropsychological Performance in Healthy Older Adults: Longitudinal Assessment in the AIBL Cohort. Frontiers in Aging Neuroscience, 2016, 8, 105.	3.4	13
378	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimerâ€™s disease. Personalized Medicine in Psychiatry, 2018, 7-8, 14-20.	0.1	13

#	Article	IF	Citations
379	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. Intelligence, 2018, 70, 22-29.	3.0	13
380	Characterization of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn. Metallomics, 2019, 11, 128-140.	2.4	13
381	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. Journal of Alzheimer's Disease, 2020, 74, 163-171.	2.6	13
382	A? peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture. Journal of Neuroscience Research, 2000, 61, 449-457.	2.9	12
383	Glycosaminoglycan sulfation determines the biochemical properties of prion protein aggregates. Glycobiology, 2015, 25, 745-755.	2.5	12
384	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. Journal of Alzheimer's Disease, 2017, 58, 193-201.	2.6	12
385	Modeling autosomal dominant Alzheimer's disease with machine learning. Alzheimer's and Dementia, 2021, 17, 1005-1016.	0.8	12
386	Major risk factors for Alzheimer's disease: age and genetics. Lancet Neurology, The, 2020, 19, 475-476.	10.2	12
387	Mesial temporal tau in amyloid-Î²-negative cognitively normal older persons. Alzheimer's Research and Therapy, 2022, 14, 51.	6.2	12
388	C-terminal peptides modelling constitutive PrPC processing demonstrate ameliorated toxicity predisposition consequent to Î±-cleavage. Biochemical Journal, 2014, 459, 103-115.	3.7	11
389	The landscape of ageingâ€"insights from AD imaging markers. Nature Reviews Neurology, 2014, 10, 678-679.	10.1	11
390	Traumatic brain injury induces elevation of Co in the human brain. Metallomics, 2015, 7, 66-70.	2.4	11
391	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimerâ€™s disease. Brain Communications, 2020, 2, fcaa102.	3.3	11
392	Plasma microRNA vary in association with the progression of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12251.	2.4	11
393	The Pathology of the Amyloid A4 Precursor of Alzheimer's Disease. Annals of Medicine, 1989, 21, 89-90.	3.8	10
394	The synthesis and spectroscopic analysis of the neurotoxic prion peptide 106â€“126: Comparative use of manual Boc and Fmoc chemistry. International Journal of Peptide Research and Therapeutics, 1999, 6, 129-134.	0.1	10
395	Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. Journal of Alzheimer's Disease, 2014, 40, 551-561.	2.6	10
396	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 50.	6.2	10

#	Article	IF	Citations
397	Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults. Journal of Clinical and Experimental Neuropsychology, 2020, 42, 55-65.	1.3	10
398	Deficits in Monocyte Function in Age Related Macular Degeneration: A Novel Systemic Change Associated With the Disease. Frontiers in Medicine, 2021, 8, 634177.	2.6	10
399	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. International Journal of Molecular Sciences, 2021, 22, 2931.	4.1	10
400	Citrullination of Amyloid-Î² Peptides in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 3719-3732.	3.5	10
401	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	2.3	10
402	The Prion Protein Preference of Sporadic Creutzfeldt-Jakob Disease Subtypes. Journal of Biological Chemistry, 2012, 287, 36465-36472.	3.4	9
403	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. International Psychogeriatrics, 2014, 26, 1737-1746.	1.0	9
404	Guanidine hydrochloride denaturation of dopamine-induced Î±-synuclein oligomers: A small-angle X-ray scattering study. Proteins: Structure, Function and Bioinformatics, 2014, 82, 10-21.	2.6	9
405	Semiâ€automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. Journal of Magnetic Resonance Imaging, 2015, 42, 1631-1638.	3.4	9
406	Magnetic Resonance Imaging of Vascular Contributions to Cognitive Impairment and Dementia. Journal of Molecular Neuroscience, 2016, 60, 349-353.	2.3	9
407	Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 441-446.	2.6	9
408	APOE É›4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2017, 57, 411-422.	2.6	9
409	CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldtâ€“Jakob disease diagnosis while transitioning to next generation diagnostics. Journal of Clinical Neuroscience, 2018, 50, 292-293.	1.5	9
410	Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry. Analytical and Bioanalytical Chemistry, 2020, 412, 1879-1892.	3.7	9
411	Genetic testing in dementiaâ€A medical genetics perspective. International Journal of Geriatric Psychiatry, 2021, 36, 1158-1170.	2.7	9
412	Tracking turncoat prion proteins. Nature, 1997, 388, 228-229.	27.8	8
413	Maximizing Safety in the Conduct of Alzheimerâ€™s Disease Fluid Biomarker Research in the Era of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 27-31.	2.6	8
414	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. Psychological Science, 2021, 32, 849-860.	3.3	8

#	Article	IF	Citations
415	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults. Frontiers in Aging Neuroscience, 2022, 14, 771214.	3.4	8
416	Enhanced ion mobility resolution of Abeta isomers from human brain using high-resolution demultiplexing software. Analytical and Bioanalytical Chemistry, 2022, 414, 5683-5693.	3.7	8
417	Buccal Cell Cytokeratin 14 Correlates withÂMultiple Blood Biomarkers ofÂAlzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2015, 48, 443-452.	2.6	7
418	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. Alzheimer's and Dementia, 2019, 15, 1448-1457.	0.8	7
419	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimerâ€™s Disease Patients and Correlates with Cognitive Performance. Journal of Alzheimer's Disease, 2020, 77, 733-744.	2.6	7
420	Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 115.	3.4	7
421	Polygenic score modifies risk for Alzheimer's disease in APOE Îµ4 homozygotes at phenotypic extremes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12226.	2.4	7
422	Learning deficit in cognitively normal APOE Îµ4 carriers with LOW Î²â€amyloid. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12136.	2.4	7
423	Neuronal Origin of Cerebral Amyloidogenic Proteins: Their Role in Alzheimer's Disease and Unconventional Virus Diseases of the Nervous System. Novartis Foundation Symposium, 1987, 126, 49-64.	1.1	7
424	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, , 1-11.	2.6	7
425	Methionine oxidation: Implications for the mechanism of toxicity of the Î²-amyloid peptide from Alzheimer's disease. International Journal of Peptide Research and Therapeutics, 2003, 10, 413-417.	1.9	6
426	CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method. Lecture Notes in Computer Science, 2016, , 109-116.	1.3	6
427	The dawn of robust individualised risk models for dementia. Lancet Neurology, The, 2019, 18, 985-987.	10.2	6
428	Decrease in p3â€AlcÎ²37 and p3â€AlcÎ²40, products of Alcadein Î² generated by Î³â€secretase cleavages, in aged monkeys and patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 740-750.	3.7	6
429	Alzheimer's disease: a clearer definition of the genetic components. Medical Journal of Australia, 1994, 160, 243-244.	1.7	6
430	Neuropathology of Unconventional Virus Infections: Molecular Pathology of Spongiform Change and Amyloid Plaque Deposition. Novartis Foundation Symposium, 1988, 135, 24-36.	1.1	6
431	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-AÎ² load and cerebrospinal fluid AÎ² in a pilot study of Alzheimerâ€™s disease. Neuroscience Letters, 2020, 731, 135078.	2.1	6
432	No Influence of Age-Related Hearing Loss on Brain Amyloid-Î². Journal of Alzheimer's Disease, 2022, 85, 359-367.	2.6	6

#	Article	IF	Citations
433	Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimerâ€™s disease. Proteome Science, 2022, 20, 2.	1.7	6
434	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimerâ€™s disease. Science Advances, 2022, 8, eabm5667.	10.3	6
435	Amyloid-Î² (AÎ²)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery. Stroke, 2022, 53, .	2.0	6
436	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. British Journal of Nutrition, 2015, 114, 1683-1693.	2.3	5
437	Alterations in dorsal and ventral posterior cingulate connectivity in APOEÎµ4 carriers at risk of Alzheimer's disease. BJPsych Open, 2015, 1, 139-148.	0.7	5
438	COMT val158met is not associated with AÎ²-amyloid and APOE Îµ4 related cognitive decline in cognitively normal older adults. IBRO Reports, 2019, 6, 147-152.	0.3	5
439	Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. Journal of Alzheimer's Disease, 2021, 79, 895-903.	2.6	5
440	SPON1 Is Associated with Amyloid-Î² and APOE Îµ4-Related Cognitive Decline in Cognitively Normal Adults. Journal of Alzheimer's Disease Reports, 2021, 5, 111-120.	2.2	5
441	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. Alzheimer's and Dementia, 2022, 18, 178-190.	0.8	5
442	Alzheimer's diseaseâ€associated presenilin 1 in neuronal cells: Evidence for localization to the endoplasmic reticulumâ€Golgi intermediate compartment. Journal of Neuroscience Research, 1997, 49, 719-731.	2.9	5
443	Soluble pool of AÎ² amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. , 1999, 46, 860.		5
444	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimerâ€™s disease, mild cognitive impairment, and healthy aging: A longitudinal study.. Psychological Assessment, 2018, 30, 1308-1316.	1.5	5
445	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF AÎ²42 moderates the association between insulin resistance and increased CSF tau levels. Neurobiology of Aging, 2022, 114, 38-48.	3.1	5
446	Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-Î². Neurobiology of Disease, 2022, 171, 105783.	4.4	5
447	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 7867.	4.1	5
448	Henryk M. Wisniewski and the amyloid theory of Alzheimer's disease. Journal of Alzheimer's Disease, 2001, 3, 83-86.	2.6	4
449	Apolipoprotein C-II Adopts Distinct Structures in Complex with Micellar and Submicellar Forms of the Amyloid-Inhibiting Lipid-Mimetic Dodecylphosphocholine. Biophysical Journal, 2016, 110, 85-94.	0.5	4
450	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	2.4	4

#	Article	IF	Citations
451	Visual Memory Deficits in Middle-Aged APOE É›4 Homozygotes Detected Using Unsupervised Cognitive Assessments. Journal of Alzheimer's Disease, 2021, 79, 1563-1573.	2.6	4
452	Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimerâ€™s Disease and Neurodegeneration. Journal of Alzheimer's Disease, 2021, 80, 1479-1489.	2.6	4
453	Comorbidity of Cerebrovascular andÂAlzheimerâ€™s Disease in Aging. Journal of Alzheimer's Disease, 2020, 78, 321-334.	2.6	4
454	Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in AÎ²â^' and AÎ²+ Older Adults. Neurology, 2022, 98, e1704-e1715.	1.1	4
455	A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping. , 2017, , .		3
456	Avoiding methodological bias in studies of amyloid imaging results disclosure. Alzheimer's Research and Therapy, 2019, 11, 52.	6.2	3
457	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimerâ€™s Disease Dementia: A Measure of Objective Memory Impairment in Amnestic Mild Cognitive Impairment. Journal of the International Neuropsychological Society, 2021, 27, 146-157.	1.8	3
458	Avoid or Embrace? Practice Effects in Alzheimerâ€™s Disease Prevention Trials. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
459	A synthetic substrate assay for the gamma-secretase of the Î²-A4 amyloid of alzheimer's disease. Journal of Peptide Science, 1995, 1, 132-139.	1.4	2
460	Amyloid Nomenclature Committee. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 151-151.	3.0	2
461	The emerging European epidemic of variant Creutzfeldtâ€“Jakob disease and bovine spongiform encephalopathy: lessons for Australia. Medical Journal of Australia, 2001, 174, 160-161.	1.7	2
462	High Order W02-Reactive Stable Oligomers of Amyloid-Î² are Produced in vivo and in vitro via Dialysis and Filtration of Synthetic Amyloid-Î² Monomer. Journal of Alzheimer's Disease, 2015, 44, 69-78.	2.6	2
463	[P1â€“444]: QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN AÎ²+ ELDERLY CONTROLS AND ALZHEIMER's DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P454.	0.8	2
464	ICâ€Pâ€167: AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE. Alzheimer's and Dementia, 2019, 15, P131.	0.8	2
465	Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients. Journal of Clinical Neuroscience, 2020, 81, 78-82.	1.5	2
466	Evaluation of GammaH2AX in Buccal Cells as a Molecular Biomarker of DNA Damage in Alzheimerâ€™s Disease in the AIBL Study of Ageing. Life, 2020, 10, 141.	2.4	2
467	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. Hormones and Behavior, 2021, 131, 104966.	2.1	2
468	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. Journal of Alzheimer's Disease, 2021, 81, 1039-1052.	2.6	2

#	Article	IF	Citations
469	Deaths with Dementia in Indigenous and Non-Indigenous Australians: A Nationwide Study. Journal of Alzheimer's Disease, 2021, 81, 1589-1599.	2.6	2
470	A Paradox in Digital Memory Assessment: Increased Sensitivity With Reduced Difficulty. Frontiers in Digital Health, 2021, 3, 780303.	2.8	2
471	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
472	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.8	2
473	Amyloid, aluminium and the aetiology of Alzheimer's disease. Medical Journal of Australia, 1996, 164, 383-383.	1.7	1
474	Shaken, Not Sonicated?. New England Journal of Medicine, 2014, 371, 571-572.	27.0	1
475	P4-388: XANAMEMTM : A Novel 11B-HSD1 Inhibitor with Potential to Provide Durable Symptomatic and Disease Modifying Benefits in Alzheimerâ€™S Disease. , 2016, 12, P1186-P1186.		1
476	[O3â€“09â€“01]: IMPLEMENTING THE CENTILOID TRANSFORMATION FOR ¹⁸Fâ€FLORBETABEN AND ¹⁸Fâ€NAV4694 USING CAPAIBL. Alzheimer's and Dementia, 2017, 13, P920.	0.8	1
477	[P4â€“255]: CORTICAL CEREBRAL MICROINFARCTS ON 3T MRI IN ALZHEIMER's DISEASE AND MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1378.	0.8	1
478	A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging. Lecture Notes in Computer Science, 2018, , 65-72.	1.3	1
479	AÎ² peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture. Journal of Neuroscience Research, 2000, 61, 449-457.	2.9	1
480	Rapidly progressive dementia with ataxia. Medical Journal of Australia, 1986, 144, 24-28.	1.7	1
481	Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial. Brain Imaging and Behavior, 2021, 15, 2833-2842.	2.1	1
482	Connecting Cohorts to Diminish Alzheimerâ€™s Disease (CONCORD-AD): A Report of an International Research Collaboration Network. Journal of Alzheimer's Disease, 2021, , 1-15.	2.6	1
483	Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: Expanding the â€˜toolkitâ€™ in the psychiatristâ€™s diagnostic armamentarium. Australian and New Zealand Journal of Psychiatry, 2022, 56, 865-866.	2.3	1
484	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. Biomedicines, 2022, 10, 1045.	3.2	1
485	Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimerâ€™s disease. BMC Genomics, 2022, 23, .	2.8	1
486	Clues to the Etiology of Alzheimer's Disease Through the Study of the Amyloid Precursor Protein. Brain Pathology, 1997, 7, 1037-1037.	4.1	0

#	Article	IF	Citations
487	Title is missing!. International Journal of Peptide Research and Therapeutics, 1999, 6, 129-134.	0.1	0
488	Crystal Structure of the N-terminal Heparin-Binding Domain of Alzheimer's Amyloid Precursor Protein. Biochemical Society Transactions, 2000, 28, A447-A447.	3.4	0
489	Annual Review of Gerontology and Geriatrics, Vol. 21. Vincent J. Cristofalo, Richard Adelman, and K. Warner Schaie (Eds.). New York: Springer Publishing Company, 2002, 296 pp., $US 58.00 (hardcover).. International Psychogeriatrics, 2002, 14, 428-429.	1.0	0
490	Iatrogenic Creutzfeldtâ€“Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?. Medical Journal of Australia, 2011, 194, 214-215.	1.7	0
491	O3-03-04: Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the australian imaging, biomarkers, and lifestyle (AIBL) study. , 2015, 11, P223-P225.		0
492	[P1â€“607]: SELFâ€REPORTED PHYSICAL ACTIVITY IS ASSOCIATED WITH TAU BURDEN AS MEASURED BY PET. Alzheimer's and Dementia, 2017, 13, P528.	0.8	0
493	[P2â€“535]: DIFFERENCES IN LONGEVITY AND DEATH CERTIFICATION ACCOUNT FOR SEX DISPARITY IN DEMENTIA MORTALITY RATES. Alzheimer's and Dementia, 2017, 13, P847.	0.8	0
494	[P3â€“224]: THE INFLUENCE OF LOWâ€DENSITY LIPOPROTEINS ON NEOCORTICAL AMYLOID LOAD IN THE AUSTRALIAN IMAGING BIOMARKER AND LIFESTYLE STUDY. Alzheimer's and Dementia, 2017, 13, P1023.	0.8	0
495	[P3â€“243]: A MASS SPECTROMETRYâ€BASED DISCOVERY AND REPLICATION OF A MULTIâ€ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1033.	0.8	0
496	[P3â€“462]: CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOIDâ€Î²2 RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLE OF HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P1150.	0.8	0
497	[P4â€“134]: INSULIN RESISTANCE IS ASSOCIATED WITH REDUCTIONS IN SPECIFIC COGNITIVE DOMAINS AND INCREASES IN CSF TAU IN COGNITIVELY NORMAL ADULTS. Alzheimer's and Dementia, 2017, 13, P1308.	0.8	0
498	[P4â€“136]: ILâ€10 AND ILâ€12/23P40 ARE JOINTLY ASSOCIATED AS PREDICTORS OF Aβâ€AMYLOID LOAD IN A BROADER BLOODâ€BASED BIOMARKER PANEL. Alzheimer's and Dementia, 2017, 13, P1308.	0.8	0
499	[P1â€“416]: CSF TOTAL TAU AS A BIOMARKER FOR NEURONAL INJURY IN ALZHEIMER's DISEASE: ALIGNING RATES OF CSF CHANGE WITH RATES OF HIPPOCAMPAL AND CORTICAL GRAY MATTER ATROPHY. Alzheimer's and Dementia, 2017, 13, P436.	0.8	0
500	[P2â€“263]: GRAPHICAL NETWORK ANALYSES INFORMS PET Aβâ€AMYLOID BIOMARKER DISCOVERY VIA QUANTIFICATION OF INDIVIDUAL PEPTIDE CONNECTIONS. Alzheimer's and Dementia, 2017, 13, P714.	0.8	0
501	P2â€364: TAU IMAGING IN ALZHEIMER'S DISEASE WITH [Fâ€18]â€MK6240, A SECOND GENERATION SELECTIVE TAU TRACER. Alzheimer's and Dementia, 2018, 14, P831.	0.8	0
502	ICâ€Pâ€223: TO TAU OR TO MAOâ€B? MOST OF THE [Fâ€18]â€THK5351 SIGNAL IS BLOCKED BY SELEGILINE. Alzheimer's and Dementia, 2018, 14, P181.	0.8	0
503	P1â€405: VISUAL ASSESSMENT OF Î²â€AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. Alzheimer's and Dementia, 2018, 14, P459.	0.8	0
504	O4â€09â€01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL Aβâ€AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P1423.	0.8	0

#	Article	IF	Citations
505	P3â€494: EXAMINING THE INFLUENCE OF UNDETECTED ATN NEUROPATHOLOGY ON COGNITIVE AGING TRAJECTORIES. Alzheimer's and Dementia, 2018, 14, P1311.	0.8	0
506	P3â€620: INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY. Alzheimer's and Dementia, 2018, 14, P1368.	0.8	0
507	O1â€04â€01: PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY. Alzheimer's and Dementia, 2018, 14, P223.	0.8	0
508	O2â€15â€03: DIFFERENTIAL RISK FACTORS FOR PROGRESSION TO MCI/DEMENTIA BY AMYLOIDâ€BETA STATUS. Alzheimer's and Dementia, 2018, 14, P661.	0.8	0
509	P1â€440: INCREASED CEREBRAL BLOOD FLOW WITH INCREASED AMYLOID BURDEN IN PRECLINICAL AD. Alzheimer's and Dementia, 2018, 14, P479.	0.8	0
510	ICâ€Pâ€008: VISUAL ASSESSMENT OF Î²â€AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. Alzheimer's and Dementia, 2018, 14, P18.	0.8	0
511	P1â€006: EXAMINING THE RESILIENCE OF SUPERAGERS: RISK OF CLINICAL PROGRESSION AND Aβ€ASSOCIATED MEMORY DECLINE OVER 8 YEARS. Alzheimer's and Dementia, 2018, 14, P264.	0.8	0
512	ICâ€Pâ€004: CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES. Alzheimer's and Dementia, 2019, 15, P15.	0.8	0
513	ICâ€Pâ€017: AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P26.	0.8	0
514	The antiâ€amyloid treatment in asymptomatic Alzheimerâ€™s disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site. Alzheimer's and Dementia, 2020, 16, e042786.	0.8	0
515	Risk factors for falls in preclinical and prodromal Alzheimerâ€™s disease and dementia due to Alzheimerâ€™s disease: Findings from the Australian Imaging, Biomarker and Lifestyle study of ageing (AIBL). Alzheimer's and Dementia, 2020, 16, e044954.	0.8	0
516	The function and composition of brain tissue derived exosomes in human Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045561.	0.8	0
517	Core Alzheimerâ€™s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. Alzheimer's Research and Therapy, 2021, 13, 79.	6.2	0
518	Creutzfeldt-Jakob disease surveillance in Australia: update to December 2016. Communicable Diseases Intelligence (2018), 2018, 42, .	0.7	0
519	Differential associations of modifiable and nonâ€modifiable dementia risk factors with memory decline and hippocampal volume loss in Aβ+and Aβ+ cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
520	Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
521	Could cerebrospinal fluid neurofilament light chain reduce misdiagnosis in neurodegenerative and neuropsychiatric disorders in a realâ€world setting? A retrospective clinical and diagnostic utility study. Alzheimer's and Dementia, 2021, 17, .	0.8	0